Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Inovio Pharmaceuticals, Inc.    INO

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Inovio Pharmaceuticals : potential COVID-19 vaccine trial on partial clinical hold

share with twitter share with LinkedIn share with facebook
09/28/2020 | 08:10am EDT

Sept 28 (Reuters) - Inovio Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration had placed a partial clinical hold on the company's planned mid-to-late-stage trial of its experimental coronavirus vaccine candidate.

The company said the pause was not due to any side effects in its early-stage study of the vaccine.

The FDA had additional questions, including about the vaccine delivery device to be used in the study, Inovio said. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)


share with twitter share with LinkedIn share with facebook
All news about INOVIO PHARMACEUTICALS, INC.
08:01aINOVIO PHARMACEUTICALS : to Report Third Quarter 2020 Financial Results on Novem..
PR
10/15INOVIO PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement (f..
AQ
10/12Stock lenders wince as hedge funds lose their shorts
RE
09/29Danger Is Approaching for Coronavirus Vaccine Stocks -- Heard on the Street
DJ
09/29INOVIO PHARMACEUTICALS : Thinking about buying stock in Sorrento Therapeutics, N..
PR
09/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
09/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
09/28China's Kangtai gets approval for clinical trial of coronavirus vaccine candi..
RE
09/28NEWS HIGHLIGHTS : Top Company News of the Day
DJ
09/28Diageo, Cleveland-Cliffs rise; Aquestive, Inovio fall
AQ
More news
Financials (USD)
Sales 2020 6,23 M - -
Net income 2020 -230 M - -
Net Debt 2020 - - -
P/E ratio 2020 -7,01x
Yield 2020 -
Capitalization 1 751 M 1 751 M -
Capi. / Sales 2020 281x
Capi. / Sales 2021 12,1x
Nbr of Employees 190
Free-Float 97,8%
Chart INOVIO PHARMACEUTICALS, INC.
Duration : Period :
Inovio Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 13,71 $
Last Close Price 10,45 $
Spread / Highest target 139%
Spread / Average Target 31,2%
Spread / Lowest Target -23,4%
EPS Revisions
Managers
NameTitle
J. Joseph Kim President, Chief Executive Officer & Director
Simon X. Benito Chairman
Jacqueline E. Shea Chief Operating Officer & Executive Vice President
Peter D. Kies Chief Financial & Accounting Officer
Laurent M. Humeau Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
INOVIO PHARMACEUTICALS, INC.231.82%1 834
LONZA GROUP AG62.80%47 152
SEAGEN INC.72.54%34 263
IQVIA HOLDINGS INC.8.39%32 108
CELLTRION, INC.31.49%28 160
MODERNA, INC.260.58%27 830